245 related articles for article (PubMed ID: 22989004)
1. Deep sequencing does not reveal additional transmitted mutations in patients diagnosed with HIV-1 variants with single nucleoside reverse transcriptase inhibitor resistance mutations.
Pingen M; van der Ende ME; Wensing AM; el Barzouhi A; Simen BB; Schutten M; Boucher CA
HIV Med; 2013 Mar; 14(3):176-81. PubMed ID: 22989004
[TBL] [Abstract][Full Text] [Related]
2. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
4. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
[TBL] [Abstract][Full Text] [Related]
5. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant.
Chetchotisakd P; Anunnatsiri S; Kiertiburanakul S; Sutthent R; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Horsakulthai M; Chasombat S; Ruxrungtham K;
J Int Assoc Physicians AIDS Care (Chic); 2006 Dec; 5(4):152-6. PubMed ID: 17101807
[TBL] [Abstract][Full Text] [Related]
6. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
[TBL] [Abstract][Full Text] [Related]
7. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
8. New trends of primary drug resistance among HIV type 1-infected men who have sex with men in Liaoning Province, China.
Zhao B; Han X; Dai D; Liu J; Ding H; Xu J; Chu Z; Bice T; Diao Y; Shang H
AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1047-53. PubMed ID: 21417755
[TBL] [Abstract][Full Text] [Related]
9. Trends in drug resistance prevalence in HIV-1-infected children in Madrid: 1993 to 2010 analysis.
de Mulder M; Yebra G; Navas A; Martin L; de Jose MI; Navarro ML; de Ory SJ; Gonzalez-Granado I; Mellado MJ; Ramos JT; Holguin A
Pediatr Infect Dis J; 2012 Nov; 31(11):e213-21. PubMed ID: 22785049
[TBL] [Abstract][Full Text] [Related]
10. 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.
Alteri C; Santoro MM; Abbate I; Rozera G; Bruselles A; Bartolini B; Gori C; Forbici F; Orchi N; Tozzi V; Palamara G; Antinori A; Narciso P; Girardi E; Svicher V; Ceccherini-Silberstein F; Capobianchi MR; Perno CF
J Antimicrob Chemother; 2011 Nov; 66(11):2615-23. PubMed ID: 21890537
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure.
Balduin M; Oette M; Däumer MP; Hoffmann D; Pfister HJ; Kaiser R
J Clin Virol; 2009 May; 45(1):34-8. PubMed ID: 19375978
[TBL] [Abstract][Full Text] [Related]
12. Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients.
Messiaen P; Verhofstede C; Vandenbroucke I; Dinakis S; Van Eygen V; Thys K; Winters B; Aerssens J; Vogelaers D; Stuyver LJ; Vandekerckhove L
Virology; 2012 Apr; 426(1):7-11. PubMed ID: 22305619
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of drug resistance in therapy-naïve HIV infected patients and detection of African HIV subtypes in Hungary.
Kanizsai S; Ghidán A; Ujhelyi E; Bánhegyi D; Nagy K
Acta Microbiol Immunol Hung; 2010 Mar; 57(1):55-68. PubMed ID: 20350879
[TBL] [Abstract][Full Text] [Related]
14. Co-circulation HIV-1 subtypes B, C, and CRF31_BC in a drug-naïve population from Southernmost Brazil: analysis of primary resistance mutations.
de Medeiros RM; Junqueira DM; Matte MC; Barcellos NT; Chies JA; Matos Almeida SE
J Med Virol; 2011 Oct; 83(10):1682-8. PubMed ID: 21837783
[TBL] [Abstract][Full Text] [Related]
15. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
Kozal MJ; Chiarella J; St John EP; Moreno EA; Simen BB; Arnold TE; Lataillade M
Antivir Ther; 2011; 16(6):925-9. PubMed ID: 21900725
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.
de Mulder M; Yebra G; Martín L; Prieto L; Mellado MJ; Rojo P; Muñoz-Fernández MÁ; Jiménez de Ory S; Ramos JT; Holguín A;
J Antimicrob Chemother; 2011 Oct; 66(10):2362-71. PubMed ID: 21810838
[TBL] [Abstract][Full Text] [Related]
18. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
[TBL] [Abstract][Full Text] [Related]
19. Evolution and viral characteristics of a long-term circulating resistant HIV-1 strain in a cluster of treatment-naive patients.
Hofstra LM; Nijhuis M; Pingen M; Mudrikova T; Riezebos-Brilman A; Simoons-Smit AM; Van Ham PM; Bierman WF; Wensing AM
J Antimicrob Chemother; 2013 Jun; 68(6):1246-50. PubMed ID: 23467175
[TBL] [Abstract][Full Text] [Related]
20. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
